254 related articles for article (PubMed ID: 28432752)
1. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
2. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
Azoulay L
Diabetes Care; 2015 Jun; 38(6):951-3. PubMed ID: 25998285
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based therapies: facing the realities of benefits versus side effects.
Lebovitz HE
Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
[No Abstract] [Full Text] [Related]
6. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
[TBL] [Abstract][Full Text] [Related]
9. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
10. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
Jermendy G
Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
[TBL] [Abstract][Full Text] [Related]
11. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
de Heer J; Göke B
Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
[TBL] [Abstract][Full Text] [Related]
13. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
[TBL] [Abstract][Full Text] [Related]
14. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
15. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
Schectman J
Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
[No Abstract] [Full Text] [Related]
16. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
[No Abstract] [Full Text] [Related]
17. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
[No Abstract] [Full Text] [Related]
18. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
[TBL] [Abstract][Full Text] [Related]
19. The safety of incretin based drugs.
Montori VM
BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
[No Abstract] [Full Text] [Related]
20. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Singh AK; Gangopadhyay KK; Singh R
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
